<DOC>
	<DOCNO>NCT00053196</DOCNO>
	<brief_summary>RATIONALE : Giving low dos chemotherapy , fludarabine busulfan , donor bone marrow peripheral blood stem cell transplant help stop growth cancer cell . It also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune system help destroy remain cancer cell ( graft-versus-tumor effect ) . Giving infusion donor 's T cell ( donor lymphocyte infusion ) transplant may help increase effect . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving immunosuppressive therapy transplant may stop happen . PURPOSE : This phase II trial study well donor bone marrow peripheral stem cell transplant work treat patient relapse hematologic cancer treatment chemotherapy autologous stem cell transplant .</brief_summary>
	<brief_title>Donor Stem Cell Transplant Treating Patients With Relapsed Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility non-myeloablative allogeneic hematopoietic stem cell transplantation demonstrate risk treatment-related mortality first 6 month acceptable rate less 40 % patient relapse hematologic malignancy prior high-dose chemotherapy autologous stem cell transplantation . - Determine response rate ( disease-specific partial complete response ) patient treat regimen . - Determine 6-month 12-month probability response patient treat regimen . - Determine distribution time-to-progression patient respond regimen . - Determine percent donor chimerism patient treat regimen . - Determine risk acute chronic graft-vs-host disease patient treat regimen . - Determine toxic effect regimen patient . - Determine disease-free overall survival patient treat regimen . OUTLINE : This open-label study . - Preparative Regimen : Patients receive fludarabine IV 30 minute day -7 -3 busulfan IV 2 hour every 6 hour ( total 8 dos ) day -4 -3 . - Graft v Host Disease ( GVHD ) Prophylaxis : Patients HLA-identical donor receive oral ( IV unable tolerate oral administration ) tacrolimus twice daily day -1 90 follow taper^* day 150 methotrexate IV day 1 , 3 , 6 . Patients match related matched unrelated donor receive oral ( IV unable tolerate oral administration ) tacrolimus twice daily day -1 180 follow taper^* tolerate ; methotrexate IV day 1 , 3 , 6 , 11 ; oral mycophenolate mofetil twice daily day -2 60 follow taper ; rabbit anti-thymocyte globulin IV 4-6 hour day -4 -1 ( total 4 dos ) . NOTE : *Tacrolimus may taper day 60-90 donor chimerism CD3+ cell less 50 % day 60 patient progressive disease - Allogeneic Stem Cell Transplantation : Patients undergo allogeneic bone marrow peripheral blood stem cell transplantation day 0 1 . Patients receive filgrastim ( G-CSF ) subcutaneously daily begin day 7 continue blood count recover . - Donor Lymphocyte Infusion ( DLI ) : After day 180 ( day 210 patient without HLA-identical donor ) , patient stable progressive disease active GVHD may receive 3 DLIs every 8 week . Patients follow within 2-3 month , every 3 month 2 year , every 6 month 3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm hematologic malignancy , include one following : Chronic lymphocytic leukemia ( CLL ) Absolute lymphocytosis great 5,000/mm^3 Lymphocytes must appear morphologically mature less 55 % prolymphocytes Lymphocyte phenotype expression CD19 CD5 Prolymphocytic leukemia ( PLL ) Morphologically confirm Absolute lymphocytosis great 5,000/mm^3 More 55 % prolymphocytes NonHodgkin 's lymphoma Hodgkin 's lymphoma Any WHO histologic subtype allow except mantle cell lymphoma Core biopsy allow contain adequate tissue primary diagnosis immunophenotyping No bone marrow biopsy sole diagnostic mean follicular lymphoma Multiple myeloma Active disease require treatment DurieSalmon stage I , II , III Acute myeloid leukemia Documented control ( i.e. , less 10 % bone marrow blast circulate blast ) Myelodysplastic syndromes Documented disease WHO criteria Must evidence relapse/progression least 6 month prior highdose chemotherapy autologous hematopoietic stem cell support Absence CD23 expression CLL PLL allow provide morphologic evidence mantle cell lymphoma Availability follow donor type : HLAidentical sibling ( 6/6 ) 9/10 match relate donor highresolution molecular type HLA A , B , C , DRB1 , DQB1 loci Only single mismatch one class I II allele allow 10/10 matched unrelated donor highresolution molecular type HLA A , B , C , DRB1 , DQB1 loci No syngeneic donor PATIENT CHARACTERISTICS : Age Under 70 Performance status Not specify Life expectancy Not specify Hematopoietic See Disease Characteristics Hepatic Bilirubin great 3 time upper limit normal ( ULN ) AST great 3 time ULN Renal Creatinine clearance least 40 mL/min Cardiovascular LVEF least 30 % MUGA Pulmonary DLCO great 40 % No symptomatic pulmonary disease Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No uncontrolled diabetes mellitus No active serious infection No known hypersensitivity E. coliderived product PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics Chemotherapy See Disease Characteristics More 4 week since prior chemotherapy Endocrine therapy Not specify Radiotherapy More 4 week since prior radiotherapy Surgery More 4 week since prior surgery</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL negative</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>